NEW YORK, Nov. 22, 2005 (PRIMEZONE) -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(r) (EIO(r)) on The Woodlands, Texas-based PharmaFrontiers Corp. (OTCBB:PFTR). The full 60-page report can be found at www.crystalra.com, or through a link located in the Investor Relations section of the PharmaFrontiers' web site at www.pharmafrontierscorp.com. This report was paid for by PharmaFrontiers Corp.
PharmaFrontiers Corp. is a biopharmaceutical company developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis (MS), cardiovascular disease, and diabetes. These therapies are based on the Company's proprietary T-cell and stem cell technologies. PharmaFrontiers' lead product, Tovaxin, is a T-cell-based therapeutic vaccine for MS, offering a unique and personalized approach to treating the disease by inducing an immune response against the autoimmune myelin-reactive T-cells (MRTCs). Tovaxin is currently in Phase I/II clinical trials and is cleared by the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) to enter a Phase IIb trial in the first quarter of 2006. Initial human trials show that T-cell vaccination (TCV) safely induces immune responses that deplete and regulate myelin-peptide reactive T-cells, thus stabilizing the disease, with the majority of patients showing improvement. Moreover, the Company is evaluating T-cell assay technology, which can be used to monitor T-cell therapy and possibly develop a product for early diagnosis of MS.
PharmaFrontiers also holds the exclusive worldwide license to adult pluripotent stem cells derived from peripheral blood monocytes that allow for the isolation, propagation, and differentiation into cells and tissues for patient-specific cell-based therapies. PharmaFrontiers is currently pursuing indications for congestive heart failure (CHF) and Type 1 diabetes with its stem cell technology. The Company also expects to conduct basic research to determine the potential use of its stem cells in other indications, such as macular degeneration, stroke, and Parkinson's disease. PharmaFrontiers is headquartered in The Woodlands, Texas.
PharmaFrontiers is listed on the OTC Bulletin Board (OTC) under the symbol PFTR.OB.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality fee-based research to small and mid-cap companies. The Company's unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal-clear, detailed report on a company (whether public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property (IP), leadership, growth strategy, competition, risks, audited financial statements, key events and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Please see back of report for complete Company disclosures.
Forward-Looking Safe Harbor Statement
To the extent that this release discusses any expectations concerning future plans, financial results or performance, such statements are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and are subject to substantial risks and uncertainties. Actual results could differ materially from those anticipated in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and reflect only management's belief and expectations based upon presently available information. These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates, LLC assumes no obligation to update any of the forward-looking statements in this release.